Inspire Medical Systems (NYSE: INSP) reported Q1 EPS of ($0.53), $0.13 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $127.9 million versus the consensus estimate of $120.06 million.

GUIDANCE:

Inspire Medical Systems sees FY2023 revenue of $580-590 million, versus the consensus of $570 million.

• Given the positive trends during the first quarter, Inspire is increasing its full year 2023 revenue guidance to between $580 million to $590 million, which would represent growth of 42% to 45% over full year 2022 revenue of $407.9 million. This compares to the prior revenue guidance of $560 million to $570 million.
• The Company is maintaining its full year 2023 gross margin guidance of 83% to 85%.
• Inspire is also maintaining its guidance relating to the opening of new U.S. medical centers of 52 to 56 per quarter, as well as its guidance of 12 to 14 new U.S. territories per quarter for the remainder of 2023.

For earnings history and earnings-related data on Inspire Medical Systems (INSP) click here.